PRGO : Summary for Perrigo Company plc Ordinary Sh - Yahoo Finance

U.S. Markets closed

Perrigo Company plc (PRGO)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
84.67+0.20 (+0.24%)
At close: 4:02PM EST

84.68 0.01 (0.01%)
After hours: 6:03PM EST

People also watch
MYLENDPALXNREGNTEVA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close84.47
Open83.80
Bid0.00 x
Ask0.00 x
Day's Range83.58 - 84.91
52 Week Range71.84 - 140.65
Volume1,843,950
Avg. Volume1,640,031
Market Cap12.14B
Beta0.67
PE Ratio (TTM)-8.40
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.58 (0.69%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire12 hours ago

    Perrigo Company plc Announces Quarterly Dividend

    DUBLIN, Feb. 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on March 21, 2017 to shareholders of record on March 3, 2017. From its beginnings in 1887 as a packager of home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC healthcare products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products and receives royalties from the sales of the multiple sclerosis drug Tysabri®.

  • PR Newswire5 days ago

    Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution

    DUBLIN, Feb. 17, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL. Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL is indicated for the symptomatic relief of cough in adults and children 6 years of age and older. Perrigo CEO John T. Hendrickson stated, "This final approval is another example of Perrigo's ongoing commitment to developing high quality value alternatives in important treatment categories.

  • PR Newswire8 days ago

    Perrigo To Release Fourth Quarter And Calendar Year 2016 Results On February 27, 2017

    DUBLIN, Feb. 14, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release financial results for its fourth quarter and calendar year 2016 on Monday, February 27, ...